title: Emerging molecularly targeted therapies in castration refractory prostate cancer.
abstract: Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer. However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease. Over the last decade, it has been recognized that despite the failure of ADT, most prostate cancers maintain some dependence on androgen and/or androgen receptor (AR) signaling for proliferation. Furthermore, androgen independent molecular pathways have been identified as drivers of continued progression of CRPC. Subsequently, drugs have been developed targeting these pathways, many of which have received regulatory approval. Agents such as abiraterone, enzalutamide, orteronel (TAK-700), and ARN-509 target androgen signaling. Sipuleucel-T, ipilimumab, and tasquinimod augment immune-mediated tumor killing. Agents targeting classic tumorogenesis pathways including vascular endothelial growth factor, hepatocyte growth factor, insulin like growth factor-1, tumor suppressor, and those which regulate apoptosis and cell cycles are currently being developed. This paper aims to focus on emerging molecular pathways underlying progression of CRPC, and the drugs targeting these pathways, which have recently been approved or have reached advanced stages of development in either phase II or phase III clinical trials.
authors.affiliation: Division of Medical Oncology, University of UT Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA.
authors.forename: Jesal C
authors.initials: JC
authors.lastname: Patel
authors.forename: Benjamin L
authors.initials: BL
authors.lastname: Maughan
authors.forename: Archana M
authors.initials: AM
authors.lastname: Agarwal
authors.forename: Julia A
authors.initials: JA
authors.lastname: Batten
authors.forename: Tian Y
authors.initials: TY
authors.lastname: Zhang
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal